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To assess the effect of FK506 on class II MHC antigen expression on 
lymphocytes recovered from bronchoalveolar lavage (BAL) in dogs 
following left lung allotransplantation, flow cytometric anlysis with 
OKIa-1 monoclonal antibody was performed. Dogs were divided into 
two groups: Group 1 (n = 6), control group (dogs without surgery); 
Group 2 (n = 23), dogs recieving left lung allotransplantation and 
immunosuppression using FK506 (0.1mg/kg/day intramuscularly). No 
significant difference existed in the percentage of OKIa-1 positive 
lymphocytes recovered from control animals (31.2 ± 11.2%) vs. 
normal allografts in Group 2 (34.8 ± 8.5%, n = 16). With rejection, 
however, the percentage of OKIa-1 positive lymphocytes increases 
significantly in Group 2: 56.2 ± 10.3% in mild rejection (n = 6) and 
91.4 ± 4.3% in moderate or severe rejection (n = 4) (p < 0.01). Chest 
radiographs appeared normal in allografted lungs with histologically 
mild rejection. The percentage of the OKIa-1 positive lymphocytes in 
BAL did not significantly change during the first, second, or third 
week following transplantation, ((32.2 ± 6.4 (n = 5), 36.4 ± 4.2 (n = 4), 
and 35.8 ± 12.3 (n = 7), respectively)) in the allografted lungs without 
rejection. 
FK506 does not affect the class II MHC antigen expression of 
lymphocytes recovered from BAL in canine allografted lungs without 
rejection. Furthermore, this compound does not change in class II 
antigen expression seen with allograft rejection.
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Introduction 
Early recognition of rejection is one of the most important 
factors in maintaining functional lung allografts. Trans-
bronchial lung biopsy (1), immunohistochemical staining
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of transbronchial biopsy specimens (2), and analysis of 
cells derived from bronchoalveolar lavage (BAL) (3-6) 
have been reported as methods of detecting early rejection. 
However, only open lung biopsy currently allows reliable 
determination of lung allograft rejection. 
 Class II major histocompatibility antigens (class II MHC 
antigens), play an important role in the initiation of immu-
nologic rejection (7). Previously, we have reported that the 
expression of class II MHC antigen on BAL lymphocytes, 
indicated by staining with a monoclonal antibody (OKIa-1), 
increased during rejection of canine allograft lungs without 
immunosuppression, and was not affected by cyclosporine 
A (CsA) (8). 
  In this study, we examined class II MHC antigen expres-
sion by flow cytometry in a canine lung allograft model 
with FK506 immunosupression. FK506 is a macrolide 
antibiotic extracted from the fungus Streptomyces tsuku-
baensis (9) that has been found to be an effective immuno-
suppressive agent in animal as well as human kidney and 
liver transplantation (10). We also assessed the effec-
tiveness of evaluating class II MHC antigen expression for 
the diagnosis of lung allograft rejection in the recipient 
dogs.
Materials and Methods 
Adult mongrel dogs weighing 10 to 15kg were used in 
these examinations. Dogs were classified into two groups: 
Group 1 (n = 6): control dogs without surgery or immuno-
supression, and Group 2 (n = 23): dogs which underwent 
left lung allotransplantation and received 0.1 mg/kg FK506 
(Fujisawa Pharm. Ltd., Japan) each day intramuscularly. 
Chest radiography was performed on days 1, 3, 5 and 7, 
and then twice a week until the animal was sacrificed. 
Bronchoalveolar Lavage 
Bronchoalveolar Lavage was performed weekly, or when 
consolidation was found on the chest radiograph, from 
postoperative day 7 to 28. After general anesthesia was
obtained via intravenous pentobarbital, a flexible fiberoptic 
bronchoscope was introduced into a subsegmental orifice 
of the lower lobe. Fifty milliliters of sterile normal saline 
was infused and then aspirated gently with a syringe. 
Lavage was repeated three or four times, and a total of 
100ml of fluid was collected. 
Cell Preparation 
The lavage fluid was filtered through one layer of sterile 
cotton gauze and a nylon mesh filter with a pore size of 
50,u m, then centrifuged at 300 x g for 6 minutes. The 
supernatant was shaken and overlaid onto 4ml 
Lymphoprep-R solution in 15ml conical centrifuge tubes 
and centrifuged at 300 x g for 30 minutes. The pellet was 
resuspended with 2ml of distilled water, 2ml of 1.8% NaCI 
and 2ml of phosphate buffered saline (PBS), and centri-
fuged at 300 x g for 10 minutes. The pellet was washed 
with 2ml of PBS, and the mononuclear cells were separated 
and resuspended in 2ml of PBS. The final cell suspension 
contained 5-10 x 106 cells/ml. 
Immunofluorescent Staining 
Two hundred microliters of cell suspension were placed 
into each of two 12 X 75mm test tubes. Ten microliters of 
mouse OKIa-1 monoclonal antibody to B lymphocytes and 
monocytes (Ortho Diagnostic Systems Inc., U.S.A.), were 
added to one tube, and 10,(.C 1 of wash media to the other as 
a control. The cell mixture was incubated in an ice water 
bath for 30 minutes with agitation every 10 minutes. Two 
milliliters of PBS were added to each tube, the cells washed 
by centrifugation at 300 x g for 10 minutes, and the 
supernatant removed with a Pasteur pipette, leaving ap-
proximately 100,xl of media in the tube. Tubes were shak-
en to resuspend the cell pellets. One hundred microliters of 
diluted (1:100) FITC-conjugated goat-anti-mouse IgG was 
added to each tube, incubated in ice water, and washed by 
centrifugation as described above. For flow cytometric 
analysis, the cells were resuspended in 2ml of PBS, and 
maintained at 0-4 °C until analyzed. 
Flow Cytometric Analysis 
The samples were analyzed on an Ortho Spectrum III Laser 
Flow Cytometry System (Ortho Diagnostic Systems, 
U.S.A.) at a wavelength of 720nm. Lymphocytes were 
differentiated by the forward and right angle scattering 
scale. Samples were evaluated on single-parameter histo-
grams displayed on a linear scale of 256 channels through a 
green filter. The presence of marker positive cells in the 
control samples was less than 2%. Results were presented 
as a percentage of marker positive cells ± the standard 
deviation.
Open Lung Biopsy 
Open lung biopsy of allograft lungs was performed after 
BAL, and graft rejection confirmed microscopically with 
hematoxylin-eosin staining of biopsy specimens. Rejection 
was histologically graded mild, moderate, or severe, ac-
cording to the Yousem classification (11). Mild rejection 
was identified by edema of the interstitium and mild per-
ivenular and later periaterial cuffing by small round and 
transformed lymphocytes. Intense perivenular, peribron-
chial, and periarterial cuffing by lymphocytes and immuno-
blasts with endotherial inflamation constituted moderate 
rejection. Severe rejection was characterized by fibrinoid 
necrosis and thrombosis of veins and arteries with hemor-
rhage and parenchymal necrosis. 
 The animals received care in compliance with the 
"Principles of Laboratory Animal Care" formulated by the 
National Society of Medical Research. Data between 
groups were compared using the Mann-Whitney U nonpa-
rametric test. A p-value of less than 0.05 was considered 
significant.
Results 
Allografted dogs survived from 7 to 86 days following 
surgery. Thirteen dogs were sacrificed after 14 days. The 
causes of death in the remaining dogs are listed in Table 1. 
Serious toxic effects of FK 506 such as severe diarrhea, 
vomiting, or emaciation accounted for the death of 3 dogs.
Table 1. Cause of death in the recipient dogs.
   Cause of death Number of dogs (survival days) 
Sacrifice 11 (day 16, 21, 26, 29, 29, 31, 41, 41, 
                       47,86) 
Rejection 3 (day 20, 32, 48) 
Toxicosis of FK-506 3 (day 21, 54, 76) 
Acute lung edema after 3 (day 7, 15, 18) 
 BAL 
Pnuemonia 2 (day 15, 17) 
Pulmonary vein 1 (day 9) 
 thrombosis 
      Total 23
 BAL followed by open lung biopsy was performed 44 
times in 21 dogs from 7 to 28 days after transplantation. 
Twenty-two BAL and biopsies were obtained in dogs with 
normal appearing chest roentgenograms, and 15 specimens 
were collected in dogs with infiltrates on radiograph. 
Rejection was histologically confirmed 21 times in lung 
biopsy specimens of 21 dogs. The number of BAL mono-
nuclear cells was higher in grafted vs. control animals. The 
percentage of OKIa-1 positive lymphocytes in allografted 
immunosuppressed dogs with rejection was significantly 
higher than in dogs without rejection (Table 2). However,
Table 2. Number of BAL mononuclear cells and percentage of 
lymphocytes or macrophages in BAL.
weeks following transplantation (Fig. 6).
          Total number of cells Lymohocytes X 100% 
           (x106/BAL100m1) Lymphocytes + Macrophages 
Control lungs 15.7 ± 21.3 (n = 14) 17.4 ± 7.2 (n = 9) 
Grafted lungs 
rejection (-) 60.8 ± 73.1 (n = 19) 9.3 ± 4.5 (n = 16) i 
Rejection (+) 40.4 ± 45.6 (n = 15) 18.9 ± 13.9 (n = 14) 
* p < 0.01
this percentage was not different from control animals. 
 There was no significant difference in the percentage of 
OKIa-1 positive lymphocytes between control lungs and 
grafted lungs without rejection ((31.2 ± 11.2% (n = 6) vs. 
34.8 ± 8.9% (n = 16)). In the lungs with rejection, the 
percentage of OKIa-1 positive cells was significantly high-
er than in control lungs or lungs without rejection, and 
reflected the severity of rejection (Fig. 1, 2, 3, 4).
Fig. 1. Percentage of BAL lymphocytes expressing antigen 
recognized by OKIa-1 monoclonal antibody. Values expressed are 
mean + standerd deviation.
 Chest radiographs appeared normal in the allografted 
lungs with histologically mild rejection, but infiltrates were 
observed in lungs with moderate and severe rejection. 
Despite the normal appearance on chest roentgenograms in 
some episodes of mild rejection, the percentage of OKIa-1 
positive lymphocytes was higher than lungs without rejec-
tion ((59.4 ± 11.0% (n = 10) vs. 38.6 ± 8.0% (n = 6)). 
This difference persisted even in lungs without rejection 
which had infiltrates on chest radiographs (32.6 ± 9.3% (n 
= 9) p < 0.01) (Fig. 5). There was no variation in the 
percentage of OKIa-1 positive lymphocytes in the alo-
grafted lungs with or without rejection over the first three
Fig. 2. The chest roentgenogram, photomicrograph (x 40), and 
cytogram and histogram of the BAL cells in a normol lung. BAL 
and open lung biopsy performed on postoperative day 7. There 
was no infiltration on chest radiograph, and no rejection micro-
scopically. The percentage of lymphocytes in the BAL mononu-
clear cells was 14.3%. OKIa-1 positive lymphocytes accounted 
for 26.2%.
Fig. 3. The chest roentgenogram, photomicrograph (x 40), and 
cytogram and histogram of the BAL cells in a lung with mild 
rejection in a dog with BAL and open lung biopsy performed day 
14 postoperatively. The chest roentgenogram showed a virturlly 
normal appearance. Perivascular cuffing was detected microscop-
ically. The percentage of lymphocytes in the BAL mononuclear 
cells was 14.4%. OKIa-1 positive lymphocytes was 60%.
Fig. 4. Chest roentgenogram, photomicrograph, and cytogram 
and histogram of the BAL cells in a lung with severe rejection in a 
dog with BAL and open lung biopsy performed on day 21 
postoperatively. The chest roentgenograph showed diffuse consol-
idation, and biopsy showed diffuse, small, round cell infiltration 
with destruction of alveolar structure. The percentage of lympho-
cytes in the BAL mononuclear cells was 66.4%. OKIa-1 positive 
lymphocytes accounted for 95.6%.
Fig. 5. Percentage of the BAL OKIa-1 positive lymphocytes in 
canine allografted lungs categorized by infiltration on chest roen-
togenography and histologic rejection.
Fig. 6. Percentage of BAL OKIa-1 positive lymphocytes in 
canine allografted lungs over time. Closed circles indicate lungs 
with rejection; open circles indicate normal allografted lungs.
Discussion 
Bronchoalveolar lavage offers a unique opportunity for 
safe and repetitive sampling of large quantities of graft-
infiltrating immunocompetent cells. The normal canine 
cellular profile of BAL fluid is 83% macrophages, 9.9% 
lymphocytes, and 4.1% neutrophils (12). After lung allo-
transplantation without immunosuppressant therapy, the 
percentage and absolute number of lymphocytes increases 
significantly, and the predominant cell type changes from 
macrophages to lymphocytes (8, 12). In this study, the 
absolute number of mononuclear cells in the BAL fluid of 
grafted lungs increased after transplantation. Although, the 
ratio of BAL lymphocytes to macrophages decreased in the 
BAL fluid of grafted lungs without rejection, the ratio in 
lungs with rejection was not different from control animals. 
This suggests that FK506 decreases the ratio of BAL lym-
phocytes to macrophages, but does not affect the profile of 
BAL cells in active rejection. 
 This study also documents that the typical increase of 
canine BAL lymphocytes expressing class II MHC antigen 
(as measured via OKIa-1 reactivity) is not impaired in 
normal allografted lungs, and increased during acute rejec-
tion despite treatment with FK506. OKIa-1 is a cross 
reactive murine monoclonal antibody to class II MHC 
antigen (13) and IgG2. OKIa-1 identifies B lymphocytes, 
activated T lymphocytes, and some monocytes. Paradis 
(14) reported that there was rapid replacement of the donor 
B-cells with those of the recipient in BAL fluid of allo-
grafted lungs within 4 weeks unless allograft rejection 
occured (3). Recently, experimental and clinical studies 
utilizing phenotypic analysis of BAL cells via monoclonal 
antibodies in lung allograft infection and rejection were 
reported. Shennib et al. (6) showed that the percentage of 
DT2-labeled cells (which is a cross-reactive murine mono-
clonal antibody reacting specifically with canine T-cells 
(15)) was significantly higher in BAL samples from canine 
lungs with rejection than in BAL from infected lungs. 
DT2-positive cells proliferate in response to allogeneic 
cells and mitogens, but are not able to stimulate allogeneic 
cells in MLC (15). Zeevi et al. (3) found that during acute 
lung rejection, there was an increase in numbers of macro-
phages, CD8+ cells (cytotoxic/suppresser T lymphocytes), 
and neutrophils. During infection, especially with Pneumo-
cystis carinii and cytomegalovirus, both CD4+ (induc-
er/helper T-cells) and CD8+ subsets were increased 
markedly (5). In the present study, the origin or subtype of 
lymphocytes with expression of class II MHC antigen is 
not known. However, we speculate that the increased 
OKIa-1 positive lymphocytes in rejected lungs without 
infection are likely to be activated T lymphocytes origi-
nating from the recipient dogs. 
 FK506 is immunosupressive in vitro at about 100 times 
lower concentrations than CsA (16). FK506 is excep-
tionally potent in inhibiting T lymphocyte-mediated immu-
nity (17). Although there is evidence that FKS06 inhibits 
interleukin-2 probuction by T-cells in vitro, little is known 
about the effect of FK506 on T- cell function in vivo (16). 
In vitro studies have suggested that FK506 impairs the 
ability of antigen presenting cells (APC) to activate CTL 
precursors in vitro (18). However, in vivo administration of 
FK506 selectively abrogates self la restricted CD4 T-helper 
function (or all T-helper cell function) in a dose-dependent 
manner, and the defect of T-helper cell function is not due 
to inhibition of APC function (20). In this present study 
FK506 did not affect number of APCs. 
 In summary FK506 did not impair the class II MHC 
antigen exression of lymphocytes recovered from bron-
choalveolar lavage in canine allografted lungs. We demon-
strated that expression of the class II MHC antigen 
increases in rejection, and that this assay is able to detect 
mild rejection without abnormal roentgenographic findings. 
Furthermore, the degree of increase in OKIa-1 positive 
cells correlated with the severity of rejection. Therefore, 
evaluation of the class II MHC antigen expression of 
bronchoalveolar lavage lymphocytes may be useful in the 
diagnosis of lung allograft rejection in dogs treated with 
FK506. However, in this study the expression of class II 
MHC antigen on BAL lymphocytes was not investigated in 
lungs with pulmonary infection including bacterial. fungal, 
or viral pneumonia, or in lungs with chronic rejection. 
Areas for further study include the possibility of differen-
tiating lung infection from rejection, and evaluating the 
correlation of lymphocyte subtypes with chronic rejection 
and bronchiolitis obliterans.
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